Inform your dentist so they can plan your treatment accordingly.
The commercially available subcutaneous GLP-1 receptor agonists effectively elicit insulin response and control glucose metabolism with daily or weekly subcutaneous injections
doi: 10.3748/wjg.v20.i22.6912 78 ValentiniLWirthEKSchweizerUHengstermannSSchaperLKoernickeTet al
Frequently asked questions (FAQs) about GLP-1 microdosing Here are some quick answers to common questions about GLP-1 microdosing, what it involves, and how it can support your goals
They work by increasing insulin secretion, decreasing appetite, and slowing gastric emptying
However, while GLP-1 RAs did not exhibit an increased risk of acute pancreatitis, DPP-4 inhibitors demonstrated a notable risk elevation (rate ratio, 1.75) [53]